Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ISIS Pharmaceuticals, Inc. (ISIS) Has Strong Momentum With Massive Drug Pipeline: Cramer

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) appears to be trending in the right direction again after a sharp decline earlier this year. The drug company, of cholesterol drug Kynamro fame, had buckled under the disappointing sales of their leading product, but a vast product pipeline is once again winning out with investors. Jim Cramer praised them for their strong momentum on CNBC today.

ISIS Pharmaceuticals, Inc.

“Isis is, I think, just an unbelievable company, and people have to recognize that, well I was going over a bunch of them last night, but I just like that company so much. 31 different drugs on the horizon, really really terrific. Acadia, we got Parkinson’s another one, but Isis is the one that I think has the real momentum […],” Cramer said.

Included among that massive drug pipeline, which ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) lists as being 34 strong, are five different drugs in phase 3 clinical testing, approaching potential approval and release to the market. Among them is a cancer drug that inhibits the production of Clusterin, a cell-survival protein that activates in response to cancer treatments, limiting their effectiveness, as well as drugs to treat spinal muscular atrophy,  and a therapy for Familial Chylomicronemia Syndrome.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has recently had to address the unfortunate issue of sharing the same name as the infamous terrorist organization. While other companies have made moves away from the name, including the ISIS Wallet payment app, which is now called Softcard, 25-year-old ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has determined to retain their name. As they don’t deal directly with the public, name image isn’t expected to have any adverse effect on their business, like it may have with the aforementioned company.

While ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) is only up 4.29% year-to-date, they have rebounded strongly from a sharp decline in the first half of the year, after a meteoric rise of more than 500% from the start of last year until February of this one. They are up 28.88% over the past three months, and over 8% this week alone. They are currently trading at $41.69 in afternoon trading.

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.